15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 22 firms covering Neurocrine Biosciences Inc, 19 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $160.00 to $246.00, a moderate spread. The average target of $195.11 sits 7% above the current $182.81. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.73 next quarter toward $12.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 ratings
Strong Buy
Strong Buy00%
Buy1986%
Hold314%
Sell00%
Strong Sell00%
Based on 22 analysts giving stock ratings to Neurocrine Biosciences Inc.
As of Jul, 18 of 21 firms rate NBIX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NBIX EPS & revenue forecast
EPS · NEXT QUARTER
$2.73
Range $1.82 – $3.77 · 14 analysts · +26% YoY
Next period, 14 analysts expect Neurocrine Biosciences Inc to earn $2.73 a share (range $1.82 – $3.77), versus $2.17 a year earlier. Full-year consensus is $9.95, growing to $12.66 the year after.
REVENUE · NEXT QUARTER
$1.0B
Range $866.0M – $1.1B · 14 analysts · +28% YoY
Revenue is expected to reach $1.0B (range $866.0M – $1.1B), +27.9% year-over-year. Full-year consensus is $3.8B, rising to $4.5B next year.
Top analysts covering Neurocrine Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NBIX.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Hold
$191.00+4.5% to target
Overall win rate
61%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #28
Buy
$175.00-4.3% to target
Overall win rate
52%
+ Follow
#3
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$215.00+17.6% to target
Overall win rate
46%
+ Follow
#4
Anupam Rama
JP Morgan · Rank #62
Buy
$185.00+1.2% to target
Overall win rate
46%
+ Follow
#5
Ami Fadia
Needham · Rank #90
Buy
$200.00+9.4% to target
Overall win rate
46%
+ Follow
NBIX stock forecast FAQ
What is NBIX's average 12-month price target?+
The 18 analysts with a live target average $195.11 for Neurocrine Biosciences Inc over the next 12 months, ranging from a $246.00 high to a $160.00 low.
Is NBIX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 22 analyst ratings, 19 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NBIX?+
The Street-high target is $246.00 (Citigroup), and the Street-low is $160.00 (Wolfe Research). The average of all 18 active targets is $195.11.
How many Wall Street analysts cover NBIX?+
22 analysts have an active rating on Neurocrine Biosciences Inc, and 18 firms carry a live 12-month price target.
Who is the most accurate analyst covering NBIX?+
Among analysts who currently cover NBIX, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Hold with a $191.00 target.
What is Neurocrine Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $2.73 per share (range $1.82 – $3.77) across 14 analysts. Full-year EPS is projected at $9.95, rising to $12.66 the following year.
How much revenue is Neurocrine Biosciences Inc expected to report next quarter?+
Consensus revenue is $1.0B (range $866.0M – $1.1B). Full-year revenue is projected at $3.8B, growing to $4.5B next year.
Have analysts been upgrading or downgrading NBIX lately?+
As of Jul, 18 of 21 firms rate NBIX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NBIX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
